A vaccine administered during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of infants dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine functions by activating the mother’s immune system to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the moment of birth, precisely when they are most vulnerable to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is given at least four weeks before delivery. Even briefer gaps between vaccination and birth can still provide substantial defence, with evidence indicating that a fortnight’s interval is adequate to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst observing that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent coverage when vaccinated 4 weeks before birth
- Antibodies from the mother passed through the placenta safeguard newborns from day one
- Coverage achievable with 2-week gap before early delivery
- Vaccination during third trimester still offers meaningful infant protection
Strong evidence from the latest research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a comprehensive study undertaken in England, analysing data from close to 300,000 babies born between September 2024 and March 2025. This constitutes approximately nine out of ten of all births during that half-year window, providing comprehensive and reliable evidence of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing strong protection for newborns during their most critical early weeks. The scale of this research offers healthcare professionals and parents-to-be with trust in the vaccine’s proven efficacy across different groups and contexts.
The results present a notable picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV during the study period, with the vast majority being infants whose mothers had not received the vaccination. This stark contrast underscores the vaccine’s critical role in preventing serious illness in newborns. The drop in hospital admissions above 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the frightening and potentially life-threatening symptoms linked to severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were able to establish clear comparisons of RSV infection rates and hospitalisations. The large sample size and comprehensive nature of the data gathering ensured that findings were statistically robust and indicative of the general population, rather than individual cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at differing periods before delivery. This allowed researchers to determine the minimum time required between vaccination and birth for best possible protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology assessed practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine works when administered across varied healthcare environments and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the hazards
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their first few months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to breathe and feed adequately. Parents often witness their babies struggling visibly, their chests heaving as they attempt to draw sufficient oxygen into their damaged lungs. Whilst most infants recover with supportive care, a small but significant proportion perish from RSV-related complications each year, making immunisation programmes a essential public health objective for safeguarding the youngest and most vulnerable individuals in the population.
- RSV causes lung inflammation, resulting in severe breathing difficulties in babies
- Approximately half of newborns catch the virus during their first few months alive
- Symptoms range from mild colds to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK infants need serious hospital treatment for RSV each year
- Few infants succumb to RSV related complications each year in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme began in 2024, health officials have highlighted the importance of pregnant women getting their jab at the best time for maximum protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns benefit from the most robust immunity from birth. Whilst the study demonstrates that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to maximise the antibodies passed to their babies through the placenta.
The guidance from health authorities remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has provided reassurance to expectant mothers that protection is still achievable with reduced timeframes between immunisation and delivery, including even a two-week gap for those giving birth ahead of schedule. This flexible approach acknowledges the practical demands of pregnancy whilst ensuring strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV poses the greatest risk of serious illness.
Regional differences in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Some areas have attained greater immunisation rates among eligible pregnant women, whilst others continue working to boost understanding and availability of the jab. These geographical variations reflect differences across healthcare infrastructure, communication strategies, and community involvement initiatives, though the national data demonstrates robust and reliable protection irrespective of geographical location.
- NHS trusts launching multiple messaging strategies to engage with pregnant women
- Inconsistencies across regions in immunisation take-up throughout England necessitate strategic intervention
- Local healthcare systems modifying schemes to align with local requirements and situations
Real-world impact and parental perspectives
The vaccine’s impressive effectiveness provides tangible benefits for families throughout the United Kingdom. With over 20,000 babies hospitalised annually due to RSV prior to the introduction of this safeguarding intervention, the 80% reduction in admissions means thousands of infants protected against critical disease. Parents no longer face the upsetting situation of watching their newborns gasping for air or labour to feed, symptoms that mark severe RSV infections. The vaccine has fundamentally shifted the picture of neonatal breathing health, providing expectant mothers a proactive tool to shield their most at-risk babies during those vital initial period.
For families like that of Malachi, whose severe RSV infection resulted in devastating brain damage, the vaccine’s introduction carries deep personal significance. His mother’s promotion of the jab underscores the life-altering consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story resonates powerfully with parents now provided with protection. The knowledge that such significant complications—hospitalisation, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to pregnant women during their final trimester, transforming what was once an inevitable seasonal threat into a manageable health risk.